• Dinesh D. Ghadigaonkar Division of Biomedical Services, Shree Dhootapapeshwar Ltd., Panvel, Maharashtra
  • MUKESH B. CHAWDA Solumiks Herbaceuticals Ltd., Mumbai, Maharashtra,
  • KAPIL S. THAKUR Quality Control Department, Shree Dhootapapeshwar Ltd., Panvel, Maharashtra
  • PAWAN K. KUSHWAH Division of Biomedical Services, Shree Dhootapapeshwar Ltd., Panvel, Maharashtra


Objective: The present research work aims to evaluate the hypolipidemic activity of arogyavardhini and zpter tablet in high fat diet (HFD) induced hyperlipidemia in wistar rats.

Methods: Wistar rats were divided in 5 groups. The normal control group received standard pellet diet. The HFD group received HFD rich in cholesterol. The HFD+Arogyavardhini group received HFD rich in cholesterol along with Arogyavardhini treatment. The HFD+zpter group received HFD rich in cholesterol along with zpter treatment. The standard Control group received HFD rich in cholesterol and treatment with Atorvastatin. Serum Lipid profile estimation and histopathological estimations done at end treatment. Group means were compared with Analysis of Variance (ANOVA) followed by Tukey‘s post-hoc analysis (P<0.05).

Result: HFD group shows significant (P<0.05) increase in total cholesterol (TC) levels (207.15 mg/dl) and triglyceride (TG) levels (223.83 mg/dl) when compared with standard pellet fed rats (TC=151.05 mg/dl and TG=164.67 mg/dl). Treatment with Arogyavardhini significantly (P<0.05) reduces the increased levels of TC (160.123 mg/dl) and TG (189.5 mg/dl) in hyperlipedimic rats. Treatment with Zpter significantly (P<0.05) reduces the increased levels of TC (163.89 mg/dl) and TG (193.167 mg/dl) in hyperlipedimic rats, which is comparable to standard treatment atorvastatin (TC= 155.81 mg/dl, TG=180.33 mg/dl).

Conclusion: The observations in this study suggest that, herbal formulations arogyavardhini and zpter have the potential to overcome hyperlipidemia.

Keywords: Ayurveda, Hyperlipidemia, Arogyavardhini, Zpter, Wistar Rats


Download data is not yet available.


1. Chen HZ. Current status of blood lipid level and treatment of hyperlipoidemia in Chinese population. J Chin Integr Med 2004;2 Suppl 2:81-2.
2. Mishra PR, Panda PK, Apanna KC, Panigrahi S. Evaluation of acute hypolipidemic activity of different plant extracts in triton WR-1339 induced hyperlipidemia in albino rats. Pharmacologyonline 2011;3:925-34.
3. Jeyabalan S, Palayan M. Antihyperlipidemic activity of sapindusemarginatus in triton WR-1339 induced albino rats. Res J Pharm Tech 2009;2:319-23.
4. Marek Iannucci S, Taylor D, Thomas A, Tucker K, Andres A, Czer LS, et al. Hyperlipidemia impairs autophagy in chronic heart failure. J Heart Lung Transplant 2018;37:S233.
5. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937–52.
6. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the european atherosclerosis society consensus panel. Eur Heart J 2017;38:2459–72.
7. Ranjan N. Management of hyperlipidemia: an update. Indian J Dermatol Venereol Leprol 2009;75:452-62.
8. World Health Organisation [Internet] Global Health observatory (GHO) data. Available from: http://www.who.int/ gho/ncd/risk_factors/cholesterol_text/en/. [Last accessed on 10 Oct 2018].
9. Kizhakkeveettil A, Jayagopal PS, Rose K. Hypercholesterolemia and ayurvedic medicine: a case report. Topics Integrative Health Care 2011;2:2006.
10. Verma N. Introduction to hyperlipidemia and its treatment: a review. Int J Curr Pharm Res 2017;9:6-14.
11. Manjiri AN, Vyas SN, Baghel MS, Ravishankar B. Randomized placebo controlled trial of mustadi ghanavati in hyperlipidemia. AYU 2010;31:287-93.
12. Joris IZ, Nunnari JJ, Krolikowski FJ, Majno G. Studies on the pathogenesis of atherosclerosis adhesion and emigration of mononuclear cells in the aorta of hypercholesterolemic rats. Am J Pathol 1983;113:341-58.
13. Golomb BA, Evans M. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008;8:373–418.
14. Guido S, Joesph T. Effect of chemically different antagonists on lipid profile in rat fed on a high fat diet. Indian J Exp Biol 1992;30:292-4.
15. Shaik J, Khan Z. Antihyperlipidemic activity of Commiphora mukul against atherogenic diet-induced hyperlipidemia in experimental rats. Asian J Pharm Clin Res 2018;11:386-9.
16. Sravanthi P, Shakir Basha S. Anti-atherosclerotic activity of ethanolic extract of chrysanthemum indicum flowers against high-fat diet-induced atherosclerosis in male wistar rats. Asian J Pharm Clin Res 2017;10:52-6.
17. Chen C, Liu L, Hsu J, Huang H, Yang M, Wang C. Mulberry extract inhibits the development of atherosclerosis in cholesterol-fed-rabbits. Food Chem 2005;91:601-7.
18. Rauch U, Osende JJ, Chasebro JH, Fuster V, Vorchheimer DA, Harris K, et al. Statin and cardiovascular disease: The multiple effects of lipid-lowering therapy by statin. Atherosclerosis 2002;153:181-9.
19. Rosenson RS. Statins in atherosclerosis. Atherosclerosis 2004;173:1-12.
20. Boden WE, Pearson TA. Raising low levels of high-density lipoprotein cholesterol is an important target of therapy. Am J Cardiol 2000;85:645-50.
21. Pedersen TR. Low density lipoprotein cholesterol lowering is and will be the key to the future of lipid management. Am J Cardiol 2001;87:8B-12B.
22. Xu Y, He Z, King GL. Introduction of hyperglycemia and dyslipidemia in the pathogenesis of diabetic vascular complications. Curr Diab Rep 2005;5:91-7.
23. Kumar G, Srivastava A, Sharma SK, Gupta YK. Safety and efficacy evaluation of ayurvedic treatment (Arjuna powder and Arogyavardhini Vati) in dyslipidemia patients: a pilot prospective cohort clinical study. Ayu 2012;33:197–201.
24. Reddy SS, Ramatholisamma P, Karunaa R, Saralakumari D. Preventive effect of Tinospora cordifolia against high-fructose diet-induced insulin resistance and oxidative stress in male wistar rats. Food Chem Toxicol 2009;47:2224-9.
25. Wing FY, Kwan PL, Wong CY, Kam TS, Chiu SM,Chan SW, et al. Attenuation of fatty liver and prevention of hypercholesterolemia by extract of Curcuma longa through regulating the expression of CYP7A1, LDL Receptor, HO?1, and HMG?CoA reductase. J Food Sci 2011;76:H80-9.
171 Views | 117 Downloads
How to Cite
Ghadigaonkar, D. D., M. B. CHAWDA, K. S. THAKUR, and P. K. KUSHWAH. “EVALUATION HYPOLIPIDEMIC ACTIVITY OF AROGYAVARDHINI AND ZPTER TABLET IN CHOLESTEROL-RICH HIGH FAT DIET (HFD) INDUCED HYPERLIPIDEMIA IN WISTAR RATS”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 11, no. 6, Apr. 2019, pp. 1-5, doi:10.22159/ijpps.2019v11i6.30805.
Original Article(s)